Eli Lilly And Co (LLY) Shares Bought by Raymond James Trust N.A.

Raymond James Trust N.A. raised its stake in shares of Eli Lilly And Co (NYSE:LLY) by 1.5% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 40,583 shares of the company’s stock after acquiring an additional 582 shares during the quarter. Raymond James Trust N.A.’s holdings in Eli Lilly And Co were worth $5,266,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of LLY. Athena Capital Advisors LLC acquired a new stake in shares of Eli Lilly And Co in the 4th quarter worth about $26,000. Wakefield Asset Management LLLP bought a new position in Eli Lilly And Co in the 4th quarter valued at about $27,000. Larson Financial Group LLC bought a new position in Eli Lilly And Co in the 4th quarter valued at about $29,000. Ironwood Financial llc bought a new position in Eli Lilly And Co in the 4th quarter valued at about $30,000. Finally, Trust Department MB Financial Bank N A grew its position in Eli Lilly And Co by 54.7% in the 1st quarter. Trust Department MB Financial Bank N A now owns 232 shares of the company’s stock valued at $30,000 after buying an additional 82 shares in the last quarter. Hedge funds and other institutional investors own 79.58% of the company’s stock.

In other news, SVP Alfonso G. Zulueta sold 4,000 shares of the firm’s stock in a transaction dated Thursday, January 31st. The shares were sold at an average price of $120.00, for a total transaction of $480,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Donald A. Zakrowski sold 1,000 shares of the firm’s stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $127.01, for a total transaction of $127,010.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 1,003,959 shares of company stock valued at $125,426,338. Insiders own 0.11% of the company’s stock.

A number of brokerages recently issued reports on LLY. Bank of America set a $129.00 target price on shares of Eli Lilly And Co and gave the company a “hold” rating in a research report on Thursday, March 21st. Credit Suisse Group set a $121.00 target price on shares of Eli Lilly And Co and gave the company a “hold” rating in a research report on Friday, March 22nd. Zacks Investment Research upgraded shares of Eli Lilly And Co from a “hold” rating to a “buy” rating and set a $142.00 target price for the company in a research report on Wednesday, April 10th. Guggenheim lowered shares of Eli Lilly And Co from a “buy” rating to a “neutral” rating and set a $125.84 target price for the company. in a research report on Thursday, April 11th. Finally, UBS Group began coverage on shares of Eli Lilly And Co in a research report on Wednesday, March 20th. They issued a “buy” rating and a $74.51 target price for the company. Ten research analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. Eli Lilly And Co presently has a consensus rating of “Buy” and an average target price of $118.02.

NYSE:LLY opened at $119.96 on Wednesday. Eli Lilly And Co has a twelve month low of $77.09 and a twelve month high of $132.13. The company has a debt-to-equity ratio of 1.07, a current ratio of 1.73 and a quick ratio of 1.38. The stock has a market cap of $128.52 billion, a PE ratio of 21.61, a price-to-earnings-growth ratio of 2.35 and a beta of 0.33.

Eli Lilly And Co (NYSE:LLY) last posted its quarterly earnings data on Wednesday, February 6th. The company reported $1.33 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $1.36 by ($0.03). Eli Lilly And Co had a net margin of 13.16% and a return on equity of 44.66%. The business had revenue of $6.44 billion for the quarter, compared to the consensus estimate of $6.28 billion. During the same quarter last year, the business posted $1.14 EPS. The business’s revenue for the quarter was up 4.5% on a year-over-year basis. Equities research analysts expect that Eli Lilly And Co will post 5.66 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: This report was posted by PressOracle and is the sole property of of PressOracle. If you are accessing this report on another website, it was illegally stolen and republished in violation of international copyright laws. The correct version of this report can be read at https://pressoracle.com/news/2019/04/17/eli-lilly-and-co-lly-shares-bought-by-raymond-james-trust-n-a.html.

Eli Lilly And Co Company Profile

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Featured Article: How to calculate the annual rate of depreciation

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.